fraction-rcc: evaluating nivolumab plus ipilimumab in patients with treatment-refractory advance...
Published 4 years ago • 257 plays • Length 5:19Download video MP4
Download video MP3
Similar videos
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
0:42
fraction-rcc: nivolumab plus ipilimumab for advanced renal cell carcinoma after progr... | rtcl.tv
-
5:52
nivolumab and salvage nivolumab plus ipilimumab for arcc
-
1:52
hcrn gu16-260: nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with adv...
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
3:14
comment: nivolumab plus ipilimumab combination for advanced nsclc
-
3:12
researcher comment: the fraction-rcc study | toni choueiri
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
4:22
cabozantinib in combination w/ nivolumab and ipilimumab of imdc intermediate or poor risk signif...
-
1:54
laurence albigès, md, phd, on patient responses to combo nivolumab ipilimumab in 1st line rcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
6:18
asco 2020: updates in renal cancer